MedTrace Logo

A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma

NCT06512428 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2024-07-22

No results posted yet for this study

Summary

To evaluate the safety and efficacy of simmitinib plus irinotecan liposome in the treatment of advanced esophageal squamous cell carcinoma, and to evaluate the PK of the drug and the correlation between biomarkers and clinical efficacy of simmitinib plus irinotecan liposome.

Conditions

  • Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG

simmitinib plus irinotecan liposome

simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks

DRUG

irinotecan liposome

irinotecan liposome 70 mg/m\^2 every 2 weeks

DRUG

irinotecan

irinotecan 180mg/m\^2 every 2 weeks

Sponsors & Collaborators

  • Shanghai Runshi Pharmaceutical Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yanqiao Zhang, Ph.D · The Second Affiliated Hospital of Harbin Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2026-01-30
Completion
2026-01-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06512428 on ClinicalTrials.gov